
Upcoming Stock Splits This Week (July 14 to July 18)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
On the flip side, some companies take a different route with a reverse stock split. Instead of dividing shares, they combine them, shrinking the overall share count and increasing the price per share. The market value doesn't budge, but this move often helps companies satisfy exchange listing requirements and avoid delisting.
Moves like these, whether designed to attract investors or simply to maintain a stock exchange listing, often serve as important signals for market-savvy traders.
Let's take a look at the upcoming stock splits for the week.
Beyond Air (XAIR) – Beyond Air focuses on developing inhaled nitric oxide therapies aimed at treating respiratory and infectious diseases. On June 20, shareholders approved a 1-for-20 reverse stock split, which is scheduled to take effect before the market opens on July 14. The primary goal of this split is to lift the company's share price above Nasdaq's $1 minimum, allowing Beyond Air to regain compliance with exchange listing requirements.
Fusion Fuel Green (HTOO) – Headquartered in Ireland, Fusion Fuel is working on advancing green hydrogen production through solar-powered PEM electrolyzers. On June 25, the company's board and shareholders approved a 1-for-35 reverse stock split, set to take effect at market open on July 14. The move is intended to bring Fusion Fuel's share price back in line with Nasdaq's minimum bid price requirements.
Lazydays Holdings (GORV) – Lazydays operates one of the largest networks of RV dealerships and service centers across the U.S., offering new and pre-owned recreational vehicles, parts, and maintenance solutions. On July 10, the board approved a 1-for-30 reverse stock split, which became effective on July 11, with trading on a split-adjusted basis beginning July 14, 2025. The split is intended to raise the company's share price and help Lazydays comply with Nasdaq's minimum bid price requirement.
NextCure (NXTC) – NextCure is a biotechnology company focused on developing immuno-oncology therapies for cancer. On June 25, shareholders approved a 1-for-12 reverse stock split, which will take effect before the market opens on July 14, 2025. The purpose of the split is to raise the stock price to satisfy exchange listing requirements.
Passage Bio Inc (PASG) – Passage Bio is a clinical-stage biotechnology company in the U.S., specializing in the development of one-time gene therapies for neurodegenerative diseases, such as its PBFT02 program. On May 28, shareholders approved a 1-for-20 reverse stock split, scheduled to take effect on July 14. The split is intended to help the company meet Nasdaq's $1.00 minimum bid price requirement.
TipRanks Stock Splits Calendar.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Small-Cap Russell 2000 Leads Another Up-Day in the Market
Thursday, July 10, 2025Markets kept moving higher this Thursday, with the small-cap Russell 2000 leading the major indexes for the 4th session in the last 5. The Dow also performed fairly well today: +192 points, +0.43%, while the S&P 500 was up +17 points or +0.27% and the Nasdaq +19 points, +0.09%. The Russell gained +10 points for the session +0.48%.The Russell 2000 has been playing catch-up of late, as large-cap AI/tech stocks listed on the Nasdaq and S&P 500 have led the market for nearly all of this year so far. But in the past month, the Russell is +5%, while the other major indexes hover around +4%. It's still off all-time highs reached 3 1/3 years ago, but the small-caps have outgained the field of the past month or much reining in animal spirits in the market these days, we continually see higher and higher markets. This is even with a trade deadline having come and gone and precious few trade deals with any U.S. trading partners helping light the way forward. We seem to be both having our cake and eating it too these days. Iconic American apparel company Levi Strauss & Co. LEVI reported earnings for its fiscal Q2 after today's close, and were ahead of the Zacks consensus estimates: earnings of 22 cents per share outshone the 14 cents estimated by analysts, while $1.4 billion in revenues surpassed the $1.37 billion we had been projecting. (You can see the full Zacks Earnings Calendar here.)Gross margins for LEVI hit a record +62.6% for the quarter, with comps for the Americas up +5%, net revenues in Europe +14%, and Asia flat. Direct-to-Consumer was +11% in the quarter. All in all, a good quarter — one that justifies its current jump +7% in late trading on the news. The stock is up an additional +14% year to date. There will be no economic reports Friday, and no earnings reports worth writing home about tomorrow either. We look ahead to next Tuesday, when not only Consumer Price Index (CPI) data will be out, but also Q2 earnings reports from some of the biggest Wall Street banks such as JPMorgan JPM, Citigroup C and Wells Fargo banks are expected to perform well, as assets under management are at record highs, while investment banking has performed well across the board with markets at or near all-time highs. The three major banks reporting Tuesday all are currently at Zacks Rank #3 (Hold). Meanwhile, the CPI Inflation Rate from last month's report was at a 12-month low +2.3%, +2.8% on core. These are about as close to what we've seen to the Fed's optimal inflation target of +2.0%.Questions or comments about this article and/or author? Click here>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Wells Fargo & Company (WFC) : Free Stock Analysis Report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Citigroup Inc. (C) : Free Stock Analysis Report Levi Strauss & Co. (LEVI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations
New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platforms. "We are excited to welcome Bowman to the CollPlant leadership team as we scale our commercial operations and development programs," said Yehiel Tal, Chief Executive Officer of CollPlant. "His deep expertise in collagen-based biomaterials, 3D bioprinting, and tissue engineering aligns perfectly with our growth strategy. Bowman's proven track record in sales, product development, licensing, and operational execution will be instrumental as we grow our bioinks portfolio and expand rhCollagen sales to the research market as well as to strategic collaborators in the fields of regenerative and aesthetic medicine." Mr. Bagley joins CollPlant from Wasatch Biolabs, a genomics research company, where he served as Vice President and Fractional CxO, leading revenue operations and growth initiatives. Previously, he spent nearly a decade at Advanced BioMatrix, a global supplier of purified collagen and extracellular matrix products, where he served as Chief Executive Officer. During his tenure, he held leadership roles across product development, business development, and global sales, helping to establish the company as a leading supplier in the research and tissue engineering space. In addition to his leadership roles, Mr. Bagley has advised life science companies on go-to-market strategies, commercial partnerships, and scaling operations. He is also an active angel investor with NuFund Venture Group, where he conducts due diligence on emerging biotech ventures. "I am honored to join CollPlant at such an exciting time in its growth trajectory," said Bowman Bagley. "CollPlant's recombinant human collagen platform represents a transformative advancement in regenerative medicine and biomaterials. I'm eager to contribute to the company's mission and help accelerate the commercial success of its innovative product portfolio, while driving long-term value for shareholders." Mr. Bagley holds a B.S. in Neuroscience from Brigham Young University and an MBA from the University of Utah. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit Forward-Looking Statements This press release includes forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods, and including its ability to conclude a non-dilutive financing transaction; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy and development plans and projects, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts CollPlant:Eran RotemDeputy CEO & CFO+ 972-73-2325600Eran@ Investors:LifeSci AdvisorsDan Ferrydaniel@ Photo - - View original content to download multimedia: SOURCE CollPlant


Business Wire
26 minutes ago
- Business Wire
Docebo to Host Second Quarter Fiscal 2025 Conference Call
TORONTO--(BUSINESS WIRE)-- Docebo Inc. (Nasdaq:DCBO; TSX:DCBO) (" Docebo" or the " Company"), a leading learning platform provider with a foundation in artificial intelligence (AI) and innovation, announced today that it will hold a conference call to discuss its second quarter fiscal year 2025 results on Friday, August 8, 2025 at 8:00 a.m. (ET). Alessio Artuffo, President and Chief Executive Officer, and Brandon Farber, Chief Financial Officer will host a live question and answer session to discuss these results. Docebo will report its financial results on the morning of Friday, August 8, 2025 prior to the call. In addition to the press release, the Company will simultaneously post a copy of management's prepared remarks (in .pdf format) on the Company's website at Second Quarter Fiscal Year 2025 Conference Call Details: Date: Time: 8:00 a.m. (ET) Dial-in number: +1.646.960.0169 or +1.888.440.6849 Italy: +39.800.595467 UK: +44.800.358.0970 Conference ID: 8722408 Live webcast: Webcast will be archived for 90 days and available at Replay: +1.609.800.9909 or +1.800.770.2030 Available until August 14, 2025 Replay passcode: 8722408 # Expand About Docebo Docebo is redefining the way enterprises leverage technology to create and manage content, deliver training, and measure the business impact of their learning programs. With Docebo's end-to-end learning platform, organizations worldwide are equipped to deliver scaled, personalized learning across all their audiences and use cases, driving growth and powering their business. Learn why businesses around the world love Docebo by visiting our customer stories page.